A study to establish the bioequivalence of free acid tafamidis 61 mg capsule and tablet, and evaluate the safety and tolerability of the 61 mg tablet in healthy adults

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514166-40-00

Acronym

B3461115

Enrollment

Registered

2024-11-14

Start date

2024-12-16

Completion date

2025-04-04

Last updated

2024-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transthyretin amyloidosis

None listed

Sex/Gender

All

Age

18 Years to No maximum

Belgium

None listed

Source: EU CTIS · Data processed: Feb 4, 2026